S. 1040: Drug Competition Enhancement Act

S. 1040 is a federal bill in the 119th Congress. Drug manufacturers currently can make minor changes to a medication as its patent expires and switch patients to this new version before generic competitors can launch, a practice known as product hopping. Under this new measure, taking such actions after… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.